Pfizer C4921003 — PF-07328948 in HFpEF
Heart Failure with Preserved Ejection Fraction (HFpEF)
Protocol: C4921003
About this study
Phase 2 study of PF-07328948, an oral branched-chain ketoacid dehydrogenase (BCKD) kinase inhibitor, in adults with heart failure. The trial evaluates the metabolic pathway that branched-chain amino acid catabolism plays in cardiac function in HFpEF.
Sponsor: Pfizer · Principal Investigator: Pedro Martinez-Clark, MD, FACC
Key eligibility
- Adults with HFpEF (LVEF ≥ 50%)
- On stable guideline-directed medical therapy
- Meeting protocol metabolic / biomarker criteria
Eligibility above is a summary. Final qualification is determined by the study protocol and a screening visit with our team.
What participation involves
Most studies follow the same general flow: a phone pre-screen, an in-person screening visit, informed consent, baseline testing, the treatment phase, and follow-up visits. Study-related care is provided at no cost. You may withdraw at any time, for any reason.
Note
This page is a plain-language overview. For the official, definitive protocol summary, please refer to ClinicalTrials.gov or speak with our coordinator.